II. Indications

  1. Hodgkins Lymphoma
    1. Brentuximab vedotin
  2. Systemic Anaplastic Large Cell Lymphoma
    1. Brentuximab vedotin

III. Mechanism

  1. CD30
    1. CD30 is a Tumor Necrosis Factor (TNF) receptor found on the surface of White Blood Cells
    2. CD30 is overexpressed in hematopoietic malignancies
  2. CD30 Monoclonal Antibody
    1. Conjugate antibodies that deliver cytotoxic drugs to CD30 positive cancer cells

IV. Medications

  1. Brentuximab vedotin (Adcetris)
    1. Conjugated Monoclonal Antibody that delivers the cytotoxic drug monomethyl auristatin E (MMAE) to cancer cells
    2. Used in Hodgkins Lymphoma

V. Dosing

  1. See other references for disease specific dosing protocols

VI. Adverse Effects

  1. Peripheral Neuropathy
  2. Infusion reactions (including Anaphylaxis)
  3. Cytopenia
    1. Neutropenia
    2. Lymphopenia
    3. Thrombocytopenia
  4. Immunosuppression
    1. Risk of opportunistic infections
  5. Hepatotoxicity
  6. Tumor Lysis Syndrome
  7. Pulmonary toxicity
  8. Severe dermatologic conditions
    1. Stevens-Johnson Syndrome
    2. Toxic Epidermal Necrolysis
  9. Other common adverse effects
    1. Hyperglycemia
    2. Gastrointestinal effects (Nausea, Vomiting, Diarrhea, Constipation, Abdominal Pain, weight loss)
    3. Stomatitis and mucositis
    4. Alopecia

VII. Safety

  1. Avoid in Lactation
  2. Avoid in pregnancy (all trimesters, Unknown Pregnancy category)
    1. Use reliable Contraception
  3. Monitoring
    1. Complete Blood Count
    2. Liver Function Tests (including Serum Bilirubin)

VIII. Drug Interactions

  1. Bleomycin
    1. Avoid in combination with Brentuximab (risk of pulmonary toxicity)

Images: Related links to external sites (from Bing)

Related Studies